SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 16th, 2021 • Cancer Genetics, Inc • Services-medical laboratories • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 10, 2021, between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CANCER GENETICS, INC.Placement Agent Agreement • February 16th, 2021 • Cancer Genetics, Inc • Services-medical laboratories • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 10, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cancer Genetics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of September 18, 2020.
STRICTLY CONFIDENTIAL Cancer Genetics, Inc.Exclusive Agency Agreement • February 16th, 2021 • Cancer Genetics, Inc • Services-medical laboratories • New York
